Details for Patent: 8,883,805

Which drugs does patent 8,883,805 protect, and when does it expire?

Patent 8,883,805 protects JENTADUETO XR, TRIJARDY XR, GLYXAMBI, JENTADUETO, and TRADJENTA, and is included in five NDAs.

Protection for JENTADUETO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-eight patent family members in thirty-four countries.

Summary for Patent: 8,883,805

Title:	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Abstract:	The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Inventor(s):	Pfrengle; Waldemar (Biberach an der Riss, DE), Pachur; Thorsten (Biberach an der Riss, DE), Nicola; Thomas (Ingelheim am Rhein, DE), Duran; Adil (Biberach an der Riss, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	13/782,149
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,883,805
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent 8,883,805

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes					Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 8,883,805

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2004 054 054	Nov 5, 2004

International Family Members for US Patent 8,883,805

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	051947
Australia	2005300559
Brazil	PI0517093
Canada	2586938
China	101048409
China	102127080
China	102391267